ABVC BioPharma, Inc.
ABVCHealthcare|Biotechnology|US
$0.97
-0.00 (-0.25%)
Tangible Book / Share
$0.47
Cash / Share
$0.00
Financials
Financial Snapshot
Market Cap
$25.9M
Enterprise Value
$27.6M
Revenue (TTM)
-$796.0K
Net Income (TTM)
-$7.9M
Cash & Investments
$94.4K
Net Cash
-$1.7M
Free Cash Flow (TTM)
-$2.4M
Operating CF (TTM)
-$2.7M
Debt/Equity
0.17
Cash Runway & Burn Rate
Cash on Hand
$94.4K
Quarterly Burn
$672.7K
Monthly Burn
$224.2K
Est. Runway
~0.1 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $18.6K | $256.9K | $40.0K | $144.3K | $5.0M | $5.9M | $1.5M | $796.1K | $928.6K | $745.8K | $94.4K | |
| Operating Cash Flow | -$3.5M | -$1.7M | -$630.2K | -$3.1M | -$4.6M | -$7.6M | -$7.4M | -$4.2M | -$1.8M | -$3.0M | -$2.7M | |
| Free Cash Flow | -$3.5M | -$1.7M | -$630.2K | -$3.1M | -$4.6M | -$7.6M | -$7.5M | -$4.2M | -$1.8M | -$3.0M | -$2.4M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$17.5K | -$119.7K | -$21.2K | $5.00 | $0.00 | $244.4K | |
| Financing Cash Flow | $2.7M | $9.3M | $593.0K | $3.1M | $9.6M | $10.0M | $4.0M | $3.9M | $2.0M | $4.6M | $2.2M |
R&D Spending
R&D (TTM)
$114.8K
R&D Intensity
—
R&D Growth vs Prior
-5.2%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $7.0K | $701.7K | $483.0K | $355.8K | $969.8K | $152.4K | $509.6K | $0.00 | -$796.0K | |
| R&D Expense | $10.0M | $3.2M | $988.7K | $1.0M | $549.7K | $1.0M | $2.7M | $1.1M | $179.3K | $121.1K | $114.8K | |
| R&D % of Revenue | — | — | 14213.9% | 149.4% | 113.8% | 282.1% | 277.7% | 697.3% | 35.2% | — | -14.4% | |
| SG&A | $997.2K | $967.1K | $1.6M | $3.1M | $8.4M | $11.1M | $13.1M | $5.6M | $5.0M | $7.0M | $6.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $7.0K | $701.7K | $483.0K | $355.8K | $969.8K | $152.4K | $509.6K | $0.00 | -$796.0K | |
| Cost of Revenue | $32.00 | $0.00 | $228.9K | $20.1K | $18.7K | $5.1K | $286.4K | $302.0K | $763.00 | $0.00 | $0.00 | |
| Gross Profit | -$32.00 | $0.00 | -$221.9K | $681.6K | $464.3K | $350.7K | $683.4K | -$149.6K | $508.8K | $0.00 | -$796.0K | |
| R&D | $10.0M | $3.2M | $988.7K | $1.0M | $549.7K | $1.0M | $2.7M | $1.1M | $179.3K | $121.1K | $114.8K | |
| SG&A | $997.2K | $967.1K | $1.6M | $3.1M | $8.4M | $11.1M | $13.1M | $5.6M | $5.0M | $7.0M | $6.1M | |
| Operating Income | -$11.0M | -$4.1M | -$2.8M | -$3.5M | -$8.5M | -$11.7M | -$15.1M | -$6.8M | -$4.7M | -$7.2M | -$7.3M | |
| Interest Expense | $10.2K | $103.5K | $462.8K | $482.0K | $405.0K | $227.2K | $294.0K | $1.3M | $825.9K | $415.9K | $155.2K | |
| Pretax Income | -$11.0M | -$4.2M | -$6.4M | -$4.0M | -$10.8M | -$11.2M | -$15.5M | -$8.0M | -$5.4M | -$8.4M | -$8.4M | |
| Net Income | -$11.0M | -$4.2M | -$5.6M | -$3.6M | -$9.8M | -$12.8M | -$16.4M | -$7.8M | -$4.9M | -$7.9M | -$7.9M | |
| EPS (Diluted) | -10.80 | -3.58 | -4.69 | -2.10 | -5.00 | -5.10 | -5.20 | -1.80 | -0.42 | -0.39 | -0.29 | |
| EBITDA | -$11.0M | -$4.1M | -$5.9M | -$3.5M | -$10.4M | -$11.0M | -$15.2M | -$6.3M | -$4.3M | -$7.4M | -$7.7M | |
| Shares Out. (M) | 1.17 | 1.19 | 1.19 | 1.75 | 1.97 | 2.51 | 3.17 | 4.34 | 11.67 | 23.26 | 26.06 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.6K | $256.9K | $40.0K | $144.3K | $5.0M | $5.8M | $1.4M | $716.8K | $863.8K | $681.5K | $31.9K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $108.1K | $75.8K | $79.3K | $64.7K | $64.4K | $62.4K | |
| Total Current Assets | $18.6K | $761.0K | $96.3K | $878.2K | $6.2M | $7.7M | $3.0M | $1.7M | $2.2M | $2.5M | $411.7K | |
| Total Assets | $18.6K | $6.6M | $96.3K | $6.9M | $14.8M | $13.7M | $10.9M | $7.8M | $7.5M | $21.1M | $19.4M | |
| Total Current Liabilities | $6.5M | $4.1M | $5.6M | $6.8M | $4.8M | $3.7M | $5.5M | $6.1M | $6.6M | $6.2M | $5.7M | |
| Long-Term Debt | $0.00 | $0.00 | $250.0K | $0.00 | $2.6M | $0.00 | $0.00 | $0.00 | $0.00 | $1.6M | $0.00 | |
| Total Liabilities | $6.5M | $4.1M | $5.8M | $7.1M | $8.9M | $4.8M | $6.3M | $6.5M | $6.8M | $7.8M | $7.1M | |
| Stockholders' Equity | -$6.5M | $1.7M | -$5.7M | -$151.0K | $6.6M | $8.8M | $4.5M | $1.6M | $1.2M | $11.1M | $10.3M | |
| Retained Earnings | -$11.5M | -$10.0M | -$19.9M | -$15.9M | -$25.6M | -$38.5M | -$54.9M | -$64.0M | -$68.9M | -$76.9M | -$79.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.5M | -$1.7M | -$630.2K | -$3.1M | -$4.6M | -$7.6M | -$7.4M | -$4.2M | -$1.8M | -$3.0M | -$2.7M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$17.5K | -$119.7K | -$21.2K | $5.00 | $0.00 | $244.4K | |
| Free Cash Flow | -$3.5M | -$1.7M | -$630.2K | -$3.1M | -$4.6M | -$7.6M | -$7.5M | -$4.2M | -$1.8M | -$3.0M | -$2.4M | |
| Investing Cash Flow | $0.00 | -$7.5M | -$156.4K | -$35.3K | -$225.4K | -$806.0K | -$1.7M | -$360.2K | $0.00 | -$1.2M | -$597.4K | |
| Financing Cash Flow | $2.7M | $9.3M | $593.0K | $3.1M | $9.6M | $10.0M | $4.0M | $3.9M | $2.0M | $4.6M | $2.2M | |
| Issuance of Stock | $2.4M | $7.7M | $0.00 | $531.1K | $7.6M | $11.1M | $3.7M | $0.00 | $31.0K | $4.3M | $528.2K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$7.3K | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $3.6M | $593.0K | $2.0M | $2.0M | -$590.8K | $350.0K | $1.3M | $15.9K | $341.3K | $8.6K | |
| Stock Based Comp. | $1.3M | $155.4K | $28.8K | $22.3K | $4.1M | $5.3M | $7.0M | $185.9K | $2.8M | $4.1M | $3.3M | |
| Net Change in Cash | -$821.3K | $156.5K | -$37.2K | -$82.3K | $4.8M | $1.6M | -$5.2M | -$674.9K | $147.0K | $463.2K | -$1.0M |
Dilution Tracker
Shares outstanding grew 1079.6% over 5 years — significant dilution
Shares Outstanding
27M
5-Year Share Growth
+1079.6%
Stock Issuance (TTM)
$528.2K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.17 | 1.19 | 1.19 | 1.75 | 1.97 | 2.51 | 3.17 | 4.34 | 11.67 | 23.26 | 26.06 | |
| Change vs Prior % | — | 1.2% | 0.3% | 47.3% | 12.7% | 27.1% | 26.4% | 36.9% | 169.3% | 99.2% | 12.0% | |
| Stock Issuance | $2.4M | $7.7M | $0.00 | $531.1K | $7.6M | $11.1M | $3.7M | $0.00 | $31.0K | $4.3M | $528.2K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$7.3K | $0.00 | $0.00 | |
| Stock Based Comp. | $1.3M | $155.4K | $28.8K | $22.3K | $4.1M | $5.3M | $7.0M | $185.9K | $2.8M | $4.1M | $3.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | -3190.5% | 97.1% | 96.1% | 98.6% | 70.5% | -98.1% | 99.9% | — | 100.0% | |
| Operating Margin % | — | — | -40031.1% | -492.9% | -1760.9% | -3290.1% | -1558.5% | -4439.2% | -923.3% | — | 918.6% | |
| Net Margin % | — | — | -80152.1% | -519.0% | -2027.0% | -3608.5% | -1693.5% | -5109.3% | -962.1% | — | 992.8% | |
| EBITDA Margin % | — | — | -85153.4% | -495.0% | -2147.2% | -3083.7% | -1567.0% | -4153.2% | -852.2% | — | 973.5% | |
| FCF Margin % | — | — | -9059.7% | -446.7% | -944.8% | -2140.3% | -775.2% | -2760.6% | -355.0% | — | 307.4% | |
| ROE % | 168.8% | -256.6% | 97.0% | 2412.3% | -148.4% | -145.2% | -368.8% | -501.1% | -399.9% | -71.2% | -71.5% | |
| ROA % | -59038.6% | -64.2% | -5791.2% | -52.6% | -66.3% | -93.7% | -150.2% | -100.0% | -65.0% | -37.5% | -40.7% | |
| ROIC % | 168.7% | -114.1% | -581.5% | -76.1% | -66.1% | -95.8% | -188.6% | -167.3% | -116.7% | -42.6% | -52.0% | |
| R&D / Revenue % | — | — | 14213.9% | 149.4% | 113.8% | 282.1% | 277.7% | 697.3% | 35.2% | — | -14.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 9988.0% | -31.2% | -26.3% | 172.6% | -84.3% | 234.3% | -100.0% | |
| Gross Profit | 0.0% | 100.0% | 0.0% | 407.1% | -31.9% | -24.5% | 94.9% | -121.9% | 440.1% | -100.0% | |
| Operating Income | -3384.5% | 62.4% | 32.7% | -24.2% | -145.9% | -37.6% | -29.1% | 55.2% | 30.5% | -52.0% | |
| Net Income | -3387.9% | 61.5% | -31.4% | 34.7% | -168.9% | -31.1% | -27.9% | 52.6% | 37.0% | -61.3% | |
| EPS (Diluted) | -93813.0% | 66.9% | -31.0% | 55.2% | -138.1% | -2.0% | -2.0% | 65.4% | 76.7% | 7.1% | |
| Operating Cash Flow | -103513.9% | 51.5% | 62.6% | -397.4% | -45.6% | -66.5% | 2.6% | 43.4% | 56.8% | -65.1% | |
| Free Cash Flow | -103513.9% | 51.5% | 62.6% | -397.4% | -45.6% | -66.9% | 1.3% | 44.0% | 57.0% | -65.1% | |
| R&D Expense | 0.0% | -68.3% | -68.8% | 6.1% | -47.6% | 82.6% | 168.3% | -60.5% | -83.1% | -32.5% | |
| SG&A Expense | 216.0% | -3.0% | 62.7% | 96.4% | 172.3% | 31.3% | 18.6% | -57.6% | -9.4% | 39.6% | |
| Total Assets | -72.7% | 35321.2% | -98.5% | 7096.0% | 113.2% | -7.2% | -20.2% | -28.8% | -3.1% | 179.3% | |
| Book Value / Share | -53826.8% | 137.5% | -331.9% | 98.5% | 4240.2% | 19.9% | -59.1% | -80.1% | -78.5% | 822.0% | |
| Debt | -100.0% | 0.0% | -34.8% | 472.4% | 47.9% | -50.7% | 2.3% | -18.9% | 15.7% | 8.4% | |
| Diluted Shares | -58.3% | 1.2% | 0.3% | 47.3% | 12.7% | 27.1% | 26.4% | 36.9% | 169.3% | 99.2% |
Valuation
P/E (TTM)At Loss
P/S-32.49
10Y Low / Med / High13.52 / 108.97 / 61483.61
P/B2.45
10Y Low / Med / High3.24 / 5.62 / 256.71
EV/EBITDAAt Loss
EV/Revenue-34.67
10Y Low / Med / High18.11 / 115.29 / 61592.86
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.47
Cash / Share
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -35.26 | -100.56 | -76.76 | -20.81 | -10.20 | -6.65 | -1.20 | -0.64 | -1.40 | -5.46 | -3.29 | |
| P/S Ratio | 0.00 | 0.00 | 61483.61 | 108.97 | 208.16 | 238.71 | 20.41 | 32.99 | 13.52 | 0.00 | -32.49 | |
| P/B Ratio | -64.67 | 256.71 | -74.39 | -506.54 | 15.24 | 9.60 | 4.44 | 3.24 | 5.62 | 4.46 | 2.45 | |
| EV/EBITDA | -38.34 | -103.90 | -72.33 | -23.29 | -9.87 | -7.51 | -1.44 | -1.12 | -2.12 | -7.04 | -3.56 | |
| EV/Revenue | 0.00 | 0.00 | 61592.86 | 115.29 | 211.82 | 231.71 | 22.49 | 46.45 | 18.11 | 0.00 | -34.67 |
Analyst Estimates & Quality
Altman Z-Score
-5.31
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 |
|---|---|
| Revenue | $35.3M |
| Net Income | $30.2M |
| EPS | $1.30 |
| # Analysts (EPS) | 1 |